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Increasing glucose consumption is thought to provide an evolutionary advantage to cancer
cells. Alteration of glucose metabolism in cancer influences various important metabolic
pathways including the hexosamine biosynthesis pathway (HBP), a relatively minor branch
of glycolysis. Uridine diphosphate N -acetylglucosamine (UDP-GlcNAc), an end product of
HBP, is a sugar substrate used for classical glycosylation and O-GlcNAcylation, a post-
translational protein modification implicated in a wide range of effects on cellular functions.
Emerging evidence reveals that certain cellular proteins are abnormally O-GlcNAc modi-
fied in many kinds of cancers, indicating O-GlcNAcylation is associated with malignancy.
Since O-GlcNAc rapidly on and off modifies in a similar time scale as in phosphorylation
and these modifications may occur on proteins at either on the same or adjacent sites,
it suggests that both modifications can work to regulate the cellular signaling pathways.
This review describes the metabolic shifts related to the HBP, which are commonly found
in most cancers. It also describes O-GlcNAc modified proteins identified in primary breast
and colorectal cancer, as well as in the related cancer cell lines. Moreover, we also discuss
the potential use of aberrant O-GlcNAcylated proteins as novel biomarkers of cancer.
Keywords: breast cancer, cancer biomarker, colorectal cancer, hexosamine biosynthesis pathway,O-GlcNAcylation,
phosphorylation
INTRODUCTION
Glucose consumption is required by living cells. Through
glycolysis, glucose is mainly broken down into pyruvate, which
enters into the tricarboxylic acid (TCA) cycle for maximum energy
production. Cancer cells, however, uptake glucose at a higher rate
and produce lactic acid rather than metabolizing pyruvate through
the TCA cycle. This adaptive metabolic shift is termed the War-
burg effect (1), leading to anaerobic glycolysis, and is thought to
provide an evolutionary advantage to cancer cells by providing
both increase bioenergetics and biosynthesis (2). Many proto-
oncogenes (e.g., Ras and Myc) and tumor suppressors (e.g., p53)
influence metabolism,and mutations in these genes can upregulate
glucose uptake in cancer cells and promote a metabolic pheno-
type supporting tumor cell growth and proliferation (3). Elevated
glucose uptake in cancer cells can be applied to monitor the loca-
tion of primary and metastatic tumor sites; for an example, using
F-18 fluorodeoxyglucose (FDG), a glucose analog, with a combi-
nation of positron emission tomography/computed tomography
(PET/CT) (4). In general, most glucose enters into the glycolytic
pathway, but a small fraction of glucose goes to the hexosamine
biosynthesis pathway (HBP). This pathway generates a nucleotide
sugar, uridine diphosphate N -acetylglucosamine (UDP-GlcNAc),
used for many reactions including a sugar donor, and in multiple
glycosylation reactions such as proteoglycan synthesis, N -linked
glycosylation, and the formation of O-linked glycoproteins or
O-GlcNAcylation (5).
The O-GlcNAc is dynamically regulated by two key enzymes:
O-GlcNAc transferase (OGT) (6) and O-GlcNAcase (OGA) (7),
for the addition and removal of a single GlcNAc residue from pro-
teins, respectively. Unlike classical glycosylation present in endo-
plasmic reticulum (ER) and golgi apparatus, O-GlcNAcylation
takes place in the cytoplasm, nucleus, and mitochondria, and is
implicated in a wide range of effects on cellular function and sig-
naling in metabolic diseases and cancer (8). Almost three decades
since its discovery, more than 1,000 O-GlcNAcylated proteins
have now been identified (9). Growing evidence reveals that O-
GlcNAcylation has extensive crosstalk with phosphorylation either
on the same or adjacent sites of various proteins (10). The interplay
of these two post-translational protein modifications (PTMs) can
work to fine-tune the regulation of target protein functions, sta-
bilization, translocation, complex formation, and enzyme activity,
which subsequently affects cellular signaling pathways. Glucose
flux into the HBP resulting in increased O-GlcNAcylation is an
emerging paradigm of the integration of metabolic and signaling
networks. This review emphasizes the recent connection between
the HBP and metabolic shifts, O-GlcNAc cycling enzymes, and
O-GlcNAcylation and phosphorylation found in most cancers. In
addition, O-GlcNAcylated proteins have been identified in pri-
mary breast and colorectal cancer (CRC) as well as in their cancer
cell lines. Moreover, O-GlcNAcylated proteins are discussed as
potential candidates for novel biomarkers of cancer.
HBP, METABOLIC SHIFTS, AND CANCER
The final end product of the HBP is UDP-GlcNAc (Figure 1),
which is built up from glucose, glutamine, fatty acid (acetyl-CoA),
and uridine. O-GlcNAc level may, therefore, be considered as a
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FIGURE 1 | Metabolic shifts through the hexosamine biosynthesis
pathway (HBP) and protein O-GlcNAcylation in cancer. The HBP produces
UDP-GlcNAc from its parts, glucose (Glc), glutamine (Gln), acetyl-CoA, and
UTP. The levels of these various metabolic inputs are all increased in cancer
cells. Glucose is transported into cells by glucose transporters (e.g., GLUT1).
Overexpression or mutation of c-Myc and Kras leads to an increase of
glucose uptake through GLUT1 activation. O-GlcNAcylation of PFK1
suppresses the enzyme activity, resulting in redirection of glucose
metabolism. GFAT is the rate-limiting enzyme for glucose entry into the HBP,
which converts Fruc-6-P and glutamine (Gln) into GlcN-6-P. Hypoxia induces
the GFAT transcription and expression. Glucosamine (GlcN) enters into cells
via the glucose transporters and is phosphorylated to GlcN-6-P by hexokinase,
bypassing GFAT. UDP-GlcNAc serves as a sugar donor of classical
glycosylation and O-GlcNAcylation. The later glycosylation, taking place in
cytoplasm, nucleus, and mitochondria, is controlled by O-GlcNAc cycling
enzymes; OGT and OGA for the addition and removal of sugar in and out of
proteins, respectively. OGT level is also upregulated, and consequently
results in an increase of O-GlcNAcylation in several kinds of cancers.
nutrient sensor for both normal physiology and disease patho-
physiology, such as diabetes and cancer. Approximately 2–4% of
glucose uptake into the cells enters into the HBP (11). Oncogenic
genes (e.g., c-Myc,Kras) and hypoxia contribute in glucose metab-
olism. Osthus et al. showed that overexpression of c-Myc directly
transactivates genes encoding glucose transporter GLUT1 and
increases glucose uptake (12). Ying et al. also reported that activa-
tion of oncogenic Kirsten rat sarcoma viral oncogene homolog
(Kras) is required in stimulating glucose uptake in an in vivo
model of pancreatic ductal adenocarcinoma (PDAC) (13). Loss
of Kras functions led to the downregulation of glucose uptake.
Moreover, the levels of metabolites of the pentose phosphate
pathway (PPP) and the HBP, as well as O-GlcNAcylation were
decreased upon Kras inactivation. The rate-limiting enzyme in the
HBP, glutamine:fructose-6-phosphate amidotransferase (GFAT)
catalyzes the conversion of fructose-6-phosphate to glucosamine-
6-phosphate. Hypoxia has been reported to induce the transcrip-
tion of GFAT gene through the hypoxia responsive element (HRE)
(14). Guillaumond et al. also showed that hypoxia increases the
levels of GFAT mRNA expression and O-GlcNAcylation in pan-
creatic cancer cells (15). Blocking of GFAT activity by azaserine
led to a decrease in hypoxic cell number, suggesting that activa-
tion of the HBP is required for survival of hypoxic pancreatic
cancer cells. Glucosamine, although normally present at low levels
in bodily fluids, enters into cells via the glucose transporters (16)
and is phosphorylated to glucosamine-6-phosphate by hexoki-
nase, thereby bypassing GFAT and elevating UDP-GlcNAc levels.
Recently, Yang et al. demonstrated that radiolabeled glucosamine
analogs can be introduced as novel agents to complement FDG
imaging to increase specificity and improve the accuracy of lesion
size in oncology applications (17). Glucosamine analogs become
UDP-GlcNAc analogs and the newly modified O-GlcNAc analog
proteins catalyzed by OGT are found in the cytoplasm and nucleus,
whereas FDG, a glucose analog, is not metabolized and remains in
the cytoplasm of cells. This method can be used to tag transcription
factors known to be modified byO-GlcNAc (e.g., Sp1 and NF-κB),
which are moved from the cytoplasm into the nucleus upon stim-
ulation or activation in cancer cells. Glucosamine analogs can,
therefore, be used in nuclear imaging to observe bio-activity in
tumors.
In cancer cells, hyperglycemia is thought to feed the HBP and
promote abnormally elevated O-GlcNAcylation of key signaling
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proteins (18, 19). Phosphofructokinase 1 (PFK1), one of the key
enzymes in the glycolysis pathway, is modified by O-GlcNAc at
Ser-529 in response to hypoxia in the lung cancer cell line, H1299
(20). This glycosylation suppressed PFK1 activity and redirected
glucose flux through the PPP, thus increasing nucleotide metabo-
lism and providing a growth advantage for cancer cells. Blocking
of O-GlcNAcylated PFK1 led to a reduction of cancer cell pro-
liferation in vitro and impaired tumor formation in vivo. Other
glycolytic enzymes also reported to be modified by O-GlcNAc
include triose phosphate isomerase (TPI) (21), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (22–25), enolase 2 (Eno2)
(22, 25–27), and pyruvate kinase M2 (PKM2) (25). Although the
glycosylation sites of these glycolytic enzymes have not been iden-
tified, their modifications could potentially modulate tumor cell
metabolism promoting proliferation.
Glutamine is a major source of energy for rapidly dividing
cells and is also an amino donor substrate for the conversion of
fructose-6-phosphate to glucosamine-6-phosphate by GFAT in the
HBP. Glutamine enters into cells via the glutamine transporter,
which is found to be overexpressed in various cancers (28, 29).
If GFAT is active, glutamine uptake in cancer cells can increase
the HBP flux, as well as UDP-GlcNAc, and O-GlcNAcylation. This
augmentation, for example, is found in human PDAC (30). In
a related context, inhibition of glutaminase, an amidohydrolase
enzyme, which generates glutamate from glutamine, led to a lower
proliferation rate in human breast cancer cells (31). This inhi-
bition also caused a reduction of GFAT activity and changes in
O-GlcNAc targets, such as OGT and transcription factor Sp1.
Moreover, removal of glutamine from the culture medium pro-
motes tumor cell differentiation and decreased proliferation; con-
versely, addition of glutamine protects cells from apoptosis and
induces proliferation (32). Thus, metabolic shifts through the HBP
flux, hyperglycemia, glutamine consumption, elevation of UDP-
GlcNAc, and O-GlcNAcylation contribute in regulating signaling
cascades and cell proliferation in cancer.
REGULATION OF O-GLcNAc CYCLING ENZYMES AND
O-GLcNAcylation
O-GlcNAcylation is tightly regulated by O-GlcNAc cycling
enzymes, OGT and OGA for the addition and removal of sugar
in and out of proteins, respectively. In human beings, there is
only a single OGT gene localized at chromosome Xq13.1 (33).
The alternative splicing of the OGT gene translates into at least
three different isoforms of OGT enzyme, including the 110-kDa
nucleocytoplasmic isoform (ncOGT), the 103-kDa mitochondrial
isoform (mOGT), and the short 78-kDa isoform (sOGT) (34).
The different isoforms of OGT differ in the number of tetra-
tricopeptide repeats (TRP) located at the N-terminal domain,
which is involved in protein interaction and is important for
protein substrate recognition (33). OGT is inhibited by various
inhibitors such as ST045849 (35). A single OGA encoding gene,
identified as meningioma-expressed antigen 5 (MGEA5), is local-
ized on chromosome 10q24.1–q24.3 (33). The two isoforms of
OGA from alternative splicing have been identified (7). The 130-
kDa isoform localizes predominantly in the cytoplasm, while the
75-kDa isoform, lacking one-third of the C-terminal domain,
resides in the nucleus (33). The N-terminal domain of OGA is
the catalytic domain, while the C-terminal domain contains a his-
tone acetyltransferase (HATs) sequence (33). This enzyme can be
inhibited with inhibitors such as PUGNAc, Thiamet G (36), and
GlcNAcstatin (37). A number of studies have revealed complex for-
mation between OGA and OGT. In a yeast-two hybrid screening
study, OGA has been reported as a binding partner of OGT (38).
The OGA-OGT complex has also been identified in combination
with mSin3A, and histone deacetylase-1 (HDAC1) when the estro-
gen and progesterone signaling are stimulated in CHO cells (39).
Therefore, it is possible that the binding between OGA and OGT
may affect the regulation of each other under specific conditions.
O-GlcNAcylation in cancer has been increasingly studied for
the past decade. Accumulating evidence reveals that the levels
of O-GlcNAcylation and its cycling enzymes in malignant tis-
sues are altered in various cancers. Recently, we showed that
O-GlcNAcylation and OGT expression levels are increased in both
breast and CRC (25, 40). As mentioned above, the O-GlcNAc
cycling enzymes OGT and OGA tightly regulate the level of O-
GlcNAcylation. Enhanced O-GlcNAcylation level corresponding
to increased OGT and decreased OGA expression is commonly
observed in various cancers including bone (41), bladder (42),
breast (26, 43–45), bile duct (46), colon (47–49), leukemia (50),
liver (51), lung (47), ovary (36), pancreas (30), and prostate (52,
53). Alteration of this glycosylation in thyroid cancer, however,
occurs in the opposite way (54). Interestingly, no mutations in
OGT and OGA genes have been reported in human cancers, sug-
gesting that these enzymes are tightly conserved. Therefore,besides
increased flux through the HBP, the altered expression of OGT
and OGA also contributes to enhancement of O-GlcNAcylation
in most cancers.
Manipulation and regulation of O-GlcNAc cycling enzymes
in cancer may be a way of stopping cancer growth. We have
shown that OGT silencing led to a reduction of anchorage-
independent growth of a breast cancer cell line, MDA-MB-231
(25). Caldwell et al. also reported that reduction of OGT in breast
cancer cells caused inhibition of tumor growth, both in vitro
and in vivo (43). OGT knockdown did not block cell growth
in a non-transformed breast cell line, MCF-10A (43). Consistent
with this finding, reduction of O-GlcNAcylation had no effect
on non-transformed pancreatic epithelial cell growth, but inhib-
ited human PDAC cell proliferation and anchorage-independent
growth, and triggered apoptosis (30). Because cancer cells appear
to overexpress OGT, strategies to reduce OGT activity or expres-
sion level are attractive as an anti-cancer approach. Recently, the
crystal structure of human OGT was solved by Lazarus et al. (55).
As mentioned above, there is only one OGT gene in mammals with
three alternative splicing isoforms, but more than one thousand
O-GlcNAc proteins have been identified so far (dbOGAP: Data-
base of O-GlcNAcylated Proteins and Sites). How does one OGT
specifically modify a wide range of target proteins? OGT actually
has protein-binding partners, which can form a transient complex
under specific stimulation such as by nutrient, stress, and hor-
mone. These partners include p38, OIP106, and OGA (38). The
binding between OGT and its adaptor specifically targets the cat-
alytic site of OGT to O-GlcNAcylate its target proteins (55). This
knowledge will accelerate the rational design of OGT inhibitors
for anti-cancer drug in the future.
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O-GLcNAc MODIFICATION AND PHOSPHORYLATION IN
CANCER
O-GlcNAcylation has been studied widely for 30 years. Novel
methodologies for enrichment of O-GlcNAc modified proteins
are now available, as well as mass spectrometric methods for their
characterization. Increasing study of O-GlcNAc proteins suggest
extensive crosstalk between O-GlcNAcylation and phosphoryla-
tion. Crosstalk between these two modifications occurs not only
by sharing their protein substrates but also by regulating each
other’s cycling enzymes. Both post-translational modifications
share many characteristics including the cycling of their substrates
at a similar time scale, the site of modification, and cellular state
(33). This becomes more complicated when several studies show
O-GlcNAcylation of many kinases (56), as well as phosphorylation
of OGT and OGA (10).
The O-GlcNAc attachment sites can be predicted using online
software (57) such as Yin-Yang and dbOGAP (Database of O-
GlcNAcylated Proteins and Sites). These programs can be used to
determine the interplay between O-GlcNAcylation and phospho-
rylation. The crosstalk betweenO-GlcNAcylation and phosphory-
lation in cancer has been observed in various biological signaling
regulators, including c-Myc (58, 59), p53 (57, 60), Snail1 (61), and
NF-κB p65 subunit (30).
c-Myc is a transcription factor regulating transcription of many
genes involved in cell proliferation, cell differentiation, and pro-
gramed cell death, and displays a reciprocal interplay between both
modifications. c-Myc at Thr-58 can be both a target for phos-
phorylation by GSK3 and O-GlcNAcylation (58, 59). Crosstalk
between these two modifications is competitive depending on
certain conditions. For example, O-GlcNAc modification at Thr-
58 of c-Myc was higher than phosphorylation at the same site
when cells are starved of serum. Serum stimulated cells showed
the opposite result, since Thr-58 shows enhanced phosphoryla-
tion and decreased O-GlcNAcylation. Moreover, point mutation
at Thr-58 in the coding region of c-myc is frequently found in
human Burkitt lymphomas (59, 62). Therefore, modifications of
this site might be crucial for tumor progression.
Yang et al. reported O-GlcNAc modification of p53 at Ser-149
in a breast cancer cell line, MCF-7 and a lung cancer cell line,
H1299 (57, 60). O-GlcNAcylation at Ser-149 reduced phosphory-
lation at Thr-155, leading to disruption of binding between Mdm2
and p53, which consequently reduced p53 ubiquitin-proteasome
degradation (57). Another study by Park et al. showed the impor-
tant role of O-GlcNAcylation of Snail1, a transcriptional repressor
of E-cadherin (61). Snail1 is phosphorylated by GSK-3β, promot-
ing its ubiquitination and degradation (63). Elevated O-GlcNAc
level caused by OGA inhibitors inhibited the phosphorylation-
mediated proteasomal degradation of Snail1 and consequently
increased Snail1 half-life in a similar manner to p53.
Nuclear factor-kappa B (NF-κB) is a well-known transcription
factor regulating cytokine production, lymphocyte activation, and
proliferation. NF-κB activation was found in lymphoma and many
solid tumors (64). NF-κB is a dimer of p65 (RelA) and p50 sub-
units. Ma et al. reported O-GlcNAc modification of NF-κB p65
subunit and IKKα/IKKβ in human PDAC (30). Phosphorylation
of the p65 subunit was increased when global O-GlcNAcylation
was reduced.
Crosstalk between O-GlcNAcylation and phosphorylation in
cancer are not always reciprocal. Examples include vimentin and
heat shock protein 27 (HSP27), as well as keratin 8 and 18. O-
GlcNAc sites of vimentin are on Ser-7, Thr-33, Ser-34, and Ser-54
(65). Alteration of O-GlcNAc level by OGA overexpression in
HeLa cells led to decreased pSer-82 level and increased pSer-
71 level in vimentin (66). Guo et al. also showed that nuclear
translocation of HSP27 observed in liver cancer cells is regu-
lated by both O-GlcNAc and phosphate groups (67). Another
study from Srikanth et al. displayed the synergistic effects of O-
GlcNAcylation and phosphorylation on keratin 8 and 18 (68). The
more O-GlcNAc modification occurs, the more phosphorylation
was observed in soluble keratins compared to filamentous form.
Moreover, increased O-GlcNAcylation and phosphorylation of
keratin 8 and 18 were observed in heat stress-induced HepG2 cells.
COLORECTAL CANCER AND O-GLcNAcylation
THE EXPRESSION LEVELS OF O-GLcNAc, OGT, AND OGA IN CRC
Colorectal cancer is one of the most common cancers worldwide.
It ranks the third in men and second in women according to
World Health Organization GLOBOCAN database, in 2012 (69).
Even though CRC is a curable cancer, its mortality rate is remark-
ably high, accounting for 8% of all cancer deaths. Many studies
are focused on molecular targets of CRC for finding biomark-
ers and improving treatments, but there is a little research on the
regulation of O-GlcNAc, OGT, and OGA in CRC.
Significantly elevated levels of OGT andO-GlcNAcylation were
observed in CRC tissues compared to adjacent normal tissues (47).
However, OGA level was not significantly enhanced in such cancer
tissue samples (47). Consistent with this finding, Phueaouan et al.
also reported that, in primary CRC patients (grade II), the upreg-
ulation of O-GlcNAcylation and OGT enzyme was found in CRC
tissues, but the expression of OGA did not differ in CRC tissue
extracts compared to normal samples (40).
Two studies reported changes in global O-GlcNAcylation of
CRC cell lines in association with biological effects. A colorectal
adenocarcinoma cell line, HT29 was transfected with the shOGT
expressing lentiviral vector in order to knockdown the OGT
gene (47). The level of O-GlcNAcylation was decreased, but this
did not reduce invasion in HT29, but did diminish anchorage-
independent growth. Increasing O-GlcNAc levels in Thiamet-G
treated HT29 cells markedly enhanced colony formation in soft
agar. Another study on the association of O-GlcNAcylation and
CRC recently indicated that the metastatic SW620 clone showed
higher O-GlcNAcylation level than the primary SW480 clone
(48). EnhancedO-GlcNAcylation by siOGA knockdown in SW620
resulted in the alteration of morphology to a fibroblast-like mor-
phology, associated with the epithelial metastatic progression, and
growth retardation. In addition, transcriptomics by microarray
analysis revealed that silencing of OGA can affect the expression
of many genes involved in cell movement and growth, as well as in
lipid and carbohydrate metabolism (48).
O-GLcNAcylated PROTEINS AND O-GLcNAc TARGETING IN CRC
A multistage carcinogenesis model of CRC progression was pro-
posed by Vogelstein et al. (70). The initial step, which changes
normal epithelium cells to early adenoma, includes mutation of
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APC (adenomatous polyposis coli) gene resulting in nuclear accu-
mulation of protooncogene β-catenin (49). Nuclear β-catenin
activates the transcription of c-Myc and cyclin D1, which are
important for cell proliferation. β-Catenin is negatively regulated
by phosphorylation leading to proteasomal degradation. Muta-
tion of β-catenin at specific amino acids stabilizes β-catenin and
subsequent nuclear localization (71). Little information has been
reported on O-GlcNAc modified proteins in CRC (Figure 2).
O-GlcNAcylated proteins were identified in the CRC molecu-
lar signaling pathway, including β-catenin (49) and Snail1 (61).
Olivier-Van Stichelen et al. found that β-catenin of the normal
colon cell line, CCD841CoN, showed less O-GlcNAcylation com-
pared to two other CRC cells, HT29 and HCT116 (72). Other work
from the same group demonstrated that β-catenin and global O-
GlcNAc levels were increased in proteins extracted from colons
of mice fed with high carbohydrate diet and Thiamet G (49).
Four O-GlcNAcylation sites on β-catenin including Ser-23, Thr-
40, Thr-41, and Thr-112 were mapped by ETD-MS/MS. Increased
global O-GlcNAcylation of CRC cells reduced phosphorylation of
β-catenin at Thr-41, located in the D box of β-catenin, which is
important for proteasomal degradation.
Snail1, a transcriptional suppressor of E-cadherin, is upregu-
lated in CRC tissues (73, 74). E-cadherin functions in cell adhesion,
which is required for cell differentiation and homeostasis of
epithelium. Suppression of E-cadherin accelerates invasion and
is associated with a more malignant phenotype and poor differen-
tiation in CRC (75). Snail1 was pulled down using sWGA affinity
from SW480 CRC cell (61), and although O-GlcNAcylated Snail1
function was not studied in this cell line, its role was proposed
according to data from HEK293 and A549 cells. O-GlcNAcylation
at Ser-112 of Snail1 has been mapped in HEK293 cell (61). As men-
tioned earlier, Ser-112 is crucial for phosphorylation-mediated
proteasomal degradation of Snail1. O-GlcNAc modification can
stabilize Snail1 and subsequently inhibit mRNA expression lev-
els of E-cadherin. Hyperglycemia also induced O-GlcNAcylation
of Snail1 and suppressed E-cadherin expression level, resulting in
stimulation of epithelial–mesenchymal transition (EMT).
Sp1, a specificity protein 1 transcription factor, regulates var-
ious genes encoding for growth factors, receptors, and proteins
involved in cell growth, apoptosis, differentiation, and immune
responses (76). O-GlcNAcylation of immunoprecipitated Sp1 in
HT29 cell was reported by Haltiwanger et al. (77). Increased
O-GlcNAcylation by treatment with PUGNAc showed a rec-
iprocal effect to phosphorylation on Sp1. However, the con-
sequence of O-GlcNAcylation of Sp1 in HT29 cell was not
reported. Interestingly, other works showed the function of O-
GlcNAcylation in protecting Sp1 from the ubiquitin-proteasome
pathway (76, 78).
FIGURE 2 | O-GlcNAcylated proteins and their targets identified in
colorectal cancer. O-GlcNAcylation stabilizes β-catenin and subsequently
translocates into the nucleus for its gene activation. O-GlcNAcylation
stabilizes Snail1, which subsequently represses E-cadherin expression
level observed in other cancer cells, suggesting a proposed mechanism for
colorectal cancer. Phosphorylation of β-catenin and Snail1 is proposed to
activate proteasomal degradation. The proposed mechanisms for other
O-GlcNAcylated proteins, including SP1, CK18, α-tubulin, hnRNPA2/B1,
hnRNPH, annexin A2, annexin A7, laminin-binding protein, and protein
DJ-1, are also indicated. Expression levels of E-cadherin, β-catenin,
caveolin-1, and IκB-β are altered corresponding to increased global
O-GlcNAcylation, so they are categorized as O-GlcNAc downstream
targets. Solid lines indicate known mechanisms, whereas dashed lines are
proposed mechanisms.
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Gel based proteomics was used by our group to study the
O-GlcNAc profile in CRC tissues (40). Eight O-GlcNAc modi-
fied proteins showed an increase in O-GlcNAcylation including
cytokeratin 18 (CK18), α-tubulin, heterogeneous nuclear ribonu-
cleoproteins (hnRNPs) A2/B1 (hnRNPA2/B1), hnRNPH, annexin
A2, annexin A7, laminin-binding protein, and protein DJ-1 (40).
CK18 was reported to be modified by O-GlcNAc in at least three
sites (Ser-30/Ser-31/Ser-49) (79). Increased O-GlcNAc-CK18 was
associated with increased solubility and decreased cellular levels,
while absence of O-GlcNAc on CK18 increased stability (68). α-
tubulin was also identified as an O-GlcNAc modified protein by
Walgren et al. (80). Increased O-GlcNAc α-tubulin resulted in a
reduced hetero-dimerization into microtubules (81). Annexin A2
and A7 play important roles in cytoskeletal formation and cell
matrix interaction. O-GlcNAcylation of annexin A2 was found to
be overexpressed in all cancer samples (7/7) (40). HnRNPA2/B1
and H are a group of RNA-binding proteins involved in vari-
ous processes in RNA metabolism including pre-mRNA splicing,
mRNA transport, and translation. Protein DJ-1 plays a role as
antioxidant and/or a molecular chaperone. Laminin-binding pro-
tein is involved in the assembly and/or stability of the ribosome in
the nucleus. Although the sites of O-GlcNAcylation of such pro-
teins have not been mapped in CRC tissues, the results presented
here showed detectable O-GlcNAc modified proteins in clinical
samples, which are promising as novel potential CRC biomarkers.
Furthermore, O-GlcNAcylation affects expression levels of a
number of genes in the SW620 cell (48). Silencing of OGA affected
the expression of about 1300 genes associated with cell movement
and growth, as well as metabolic pathways involving lipids and car-
bohydrates. Among these, E-cadherin, β-catenin, and caveolin-1
proteins were upregulated, while IκB-β was downregulated when
the cell was transfected by siOGA or Thiamet-G treatment, respec-
tively. This also suggests that alteration of O-GlcNAcylation plays
a vital role in the regulation of gene expression in CRC.
BREAST CANCER AND O-GLcNAcylation
THE EXPRESSION LEVELS OF O-GLcNAc, OGT, AND OGA IN BREAST
CANCER
Breast cancer is the most frequently observed cancer among
women with an estimated 1.67 million new cancer cases diagnosed
in 2012 (25% of all cancers). Moreover, breast cancer ranks as the
fifth cause of death from cancer overall (69). Many women who
develop breast cancer have no obvious risk factors for breast cancer.
Since intervention cannot always guarantee prevention of breast
cancer, more research is required for identification and develop-
ment of early stage biomarkers and molecular targets for effective
drug treatment.
Several studies of O-GlcNAc and its cycling enzyme expression
have been studied in breast cancer. In 2001, Slawson et al. found
that O-GlcNAcylation was decreased and this is due to an increase
in hexosaminidase and OGA activity in primary breast tumors,
compared to matched normal adjacent breast tissues (82). How-
ever, Dahl et al. reported a gene named MGEA5 coding for OGA,
which showed about 56% reduction in expression in breast cancer
tissues (83). Several groups, including Gu et al. (44), Caldwell
et al. (43), Krzeslak et al. (84), and our group (25), showed that the
expression of O-GlcNAcylation and OGT are upregulated, while
the OGA expression is downregulated in breast cancer. Manipula-
tion of OGT and OGA activities in breast cancer cells showed that
overexpression of OGT enhanced the migration/invasion of breast
cancer cells in vitro and lung metastasis in vivo, but did not affect
cell proliferation (44). Conversely, reduction of O-GlcNAcylation
through RNA interference of OGT in breast cancer cells led to inhi-
bition of tumor growth both in vitro and in vivo (43). Similarly,
OGT silencing resulted in a reduction of anchorage-independent
growth of a breast cancer cell line, MDA-MB-231 (25). Recently,
increased O-GlcNAcylation level was found to protect the breast
cancer cell line,MCF-7 from tamoxifen induced cell death,whereas
siRNA mediated OGT knockdown had opposite effects (85). These
data suggest that OGT may represent a novel therapeutic target
of cancer, especially in overcoming tamoxifen resistance in breast
cancer.
O-GLcNAcylated PROTEINS AND O-GLcNAc TARGETING IN BREAST
CANCER
Many groups of researchers have reported O-GlcNAc targets
in breast cancer (Figure 3).Growing evidence suggests that O-
GlcNAc plays vital roles in the regulation of cellular adhesion and
cytoskeletal formation. Gu et al. showed that O-GlcNAcylation
of p120 and β-catenin played roles in decreasing the level of E-
cadherin at the cell surface (44). E-cadherin was also reported to be
modified by O-GlcNAc at its cytoplasmic domain in breast cancer
(86). Later, Geng et al. showed that O-GlcNAcylated E-cadherin
interferes with the binding of Type I gamma phosphatidylinosi-
tol phosphate kinase (PIPKIγ), a protein required for recruitment
of E-cadherin to adhesion sites, leading to reduced E-cadherin
trafficking to the plasma membrane and accelerated apoptosis
(87). Other O-GlcNAcylated proteins found in breast cancer and
described earlier in terms of their function are p53 (60) and
Snail1 (61).
In a related context, cofilin, a family of actin-binding pro-
teins, which disassembles actin filaments, has also been reported
to be modified by O-GlcNAc at Ser-108 and this glycosylation
is essential for invadopodia formation, a process involving extra-
cellular matrix (ECM) degradation during cancer invasion and
metastasis (88). Decrease in its O-GlcNAcylation leads to the
destabilization of invadopodia and impairs the invasion of breast
cancer cells. Komura et al. reported that GlcNAc polymers and
O-GlcNAc proteins induce the expression of vimentin and cell
migration in MCF-7 (89). Regulation of vimentin expression by
GlcNAc may play a crucial role for the EMT. We also showed that
vimentin, cytokeratin 18 (CK18), β-actin, and keratin 7 appeared
to show increased O-GlcNAcylation in breast cancer tissues, but
their glycosylation sites were not yet mapped (25).
Glycolytic enzymes are also targets ofO-GlcNAcylation. Several
glycolytic enzymes were hyper-O-GlcNAcylated in breast cancer
tissues. Using O-GlcNAc gel based proteomics, four glycolytic
enzymes including enolase 2 (ENO2), TPI, pyruvate kinase M2
(PKM2), and GAPDH were identified (25). O-GlcNAcylation of
enolase 1 (ENO1) was also reported in a breast cancer cell line,
T47D (26), but the glycosylation sites have not yet been identified.
Interestingly, as described earlier, O-GlcNAc at Ser-529 of phos-
phofructokinase 1 (PFK1) inhibited its activity and redirected glu-
cose flux through the PPP (20). Recently, Ferrer et al. demonstrated
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FIGURE 3 | O-GlcNAcylated proteins and their targets identified in
breast cancer. O-GlcNAcylation modifies many proteins in both the
cytoplasm and nucleus. p120, β-catenin, and E-cadherin are glycosylated,
and this modification regulates E-cadherin localization and stability.
O-GlcNAc Snail1 suppresses E-cadherin expression. Phosphorylation of
β-catenin and Snail1 can activate proteasomal degradation while O-GlcNAc
p53 protects this event. Other cytoskeletal proteins (cofilin, β-actin,
vimentin, keratin 7, annexin A2, and CK18), glycolytic enzymes (PKF1,
PKM2, GAPDH, TPI, ENO2, and ENO1), chaperones (protein DJ1, HSC70,
HSP27, PDIA6, peroxiredoxin 3, 4, and 6), thymidine phosphorylase, and
VDAC1 are also O-GlcNAcylated. Nuclear proteins including hnRNPs and
proteins related to transcription and translation are O-GlcNAcylated as
indicated. Alteration of this modification also regulates gene and protein
expressions in breast cancer including FoxM1 and EZH2. Solid lines
indicate known mechanisms, whereas dashed lines are proposed
mechanisms.
that O-GlcNAcylation regulates glycolysis in cancer cells via
hypoxia-inducible factor 1 (HIF-1α) and glucose transporter type
1, GLUT1 (90). Reducing O-GlcNAcylation led to HIF-1α degra-
dation and activation of ER stress and apoptosis. In addition,
human breast cancers with high HIF-1α and OGT levels, and low
OGA levels are correlated with poor patient outcome. This suggests
that the combined detection of HIF-1α, OGT, and OGA in clinical
samples may be useful as potential breast cancer biomarkers.
Heterogeneous nuclear ribonucleoproteins are also a major
group of proteins modified by O-GlcNAc in breast cancer. The
hnRNPs are complexes of RNA and proteins that are involved in
multiple aspects of RNA processing and modifications. Five mem-
bers of hnRNPs including hnRNP U-like protein 2, hnRNPK,
hnRNPF, hnRNPM, and hnRNPA2/B1 showed increased O-
GlcNAcylation in breast cancer tissues (25), while other work by
Rambaruth et al. showed that hnRNP H1, hnRNP D-like, hnRNP
A2/B1 were hyper-O-GlcNAcylated in breast cancer cells (26).
Although their glycosylation sites were not identified, increasedO-
GlcNAcylation in the hnRNP family may act as a novel regulation
of alternative mRNA processing and gene expression, and that pro-
motes a beneficial phenotype for cancer. In addition, two proteins
in the nucleus involved in transcription and translation, riboso-
mal protein SA (RSSA) and far upstream element-binding protein
1 (FUSE-BP1), showed increasedO-GlcNAcylation in cancer (25).
Chaperones and stress response proteins also show O-GlcNAc
modification. We reported that heat shock cognate proteins
(HSC70), protein disulfide isomerase (PDI) A6, peroxiredoxin 3,
4, and 6, and protein DJ-1 are O-GlcNAcylated in breast can-
cer tissues (25), while Rambaruth et al. showed O-GlcNAcyation
of HSP27 (26). However, the effect of this modification on
chaperones and stress response function is still not clear.
Two other proteins may be hyper O-GlcNAcylated: thymi-
dine phosphorylase (TP), an enzyme involved in nucleic acid
metabolism, and voltage dependent anion selective channel pro-
tein 1 (VDAC1), a mitochondrial protein that may contribute in
triggering apoptosis (25).
O-GlcNAcylation also regulates gene and protein expres-
sion in breast cancer. Caldwell et al. showed that decreasing
O-GlcNAcylation using RNA interference against OGT led to
decreased cell invasion, tumor growth, and angiogenesis, both
in vitro and in vivo, and this reduction is associated with decreased
expression and activity of the oncogenic transcription factor
FoxM1 (43). Recently, Chu et al. showed that the enhancer of
zeste homolog 2 (EZH2), an enzyme, which acts as a gene silencer
by histone methylation, is O-GlcNAcylated at Ser-75 (91). OGT
knockdown reduced the EZH2 expression and H3 trimethylation
at K-27 in MCF-7, indicating that O-GlcNAcylation of EZH2 is
required for EZH2 stability.
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CONCLUSION AND PERSPECTIVES
Current information strongly suggests that alteration of cellu-
lar metabolism from mitochondrial oxidative phosphorylation
to aerobic glycolysis provides both bioenergetics and biosynthe-
sis capability for cancer cells. Increasing glucose uptake and the
redirection of glucose to the HBP flux can lead to an increase of
UDP-GlcNAc and O-GlcNAcylation levels in cancer. Mutation of
genes involving glucose uptake also contributes to this. In addition,
O-GlcNAc cycling enzymes are altered in most cancers. Changes in
O-GlcNAc and OGT levels clearly show positive relationship with
the histological grade of breast and colorectal tumors. Greater
increases in O-GlcNAc levels correlated with higher grades of
tumor development. Importantly, this modification has extensive
crosstalk with phosphorylation, which consequently affects cel-
lular signaling. Thus, metabolic shifts through the HBP flux and
O-GlcNAcylation contribute to regulation of signaling cascades
and cell proliferation in cancer.
Study of O-GlcNAcylation in cancer is rapidly growing in
terms of both detection and functional studies using in vitro and
in vivo models. Several O-GlcNAc modified proteins have been
discovered in breast and CRC. However, more O-GlcNAcylated
proteins have been identified in breast cancer in comparison with
CRC. This may result from differences in protein expression in
each specific organ, as well as the tumor grade examined in
the study. In addition, the levels of O-GlcNAc cycling enzymes
differ. In breast cancer, major identified proteins are glycolytic
enzymes and proteins, which function in biosynthesis (nucleic
acid metabolism). The modified protein groups shared in breast
and CRC are (1) proteins, which function in the stress responses;
(2) hnRNPs and proteins involved in transcription and transla-
tion; (3) proteins related to the cytoskeleton and their regulation;
and (4) transcription factors (e.g., Snail1 and β-catenin), which
are difficult to observe and need to be enriched before detec-
tion. In addition, a number of O-GlcNAc targets in breast and
CRC are not shown to be modified directly but rather regu-
late gene and/or protein expression such as FoxM1, Caveolin-1,
and IκB-β. Moreover, more O-GlcNAc modified proteins were
identified from breast cancer tissues than from breast cancer cell
lines, indicating the complexity of O-GlcNAc regulation in vivo
(25). O-GlcNAc modified proteins identified from clinical sam-
ples are thus more realistic as potential novel cancer biomarkers.
Examples are PKM2 in breast cancer (25) and annexin A2 in
CRC (40). However, larger scale studies need to be performed
to obtain information with greater accuracy and reliability for
possible use in clinical detection. On another hand, O-GlcNAc
research on cell lines is also needed in order to test mechanisms
and functions. A good example is that of O-GlcNAcylation of
PFK1, which leads to decrease in activity and redirection of glu-
cose metabolism in cancer cell lines (20). Alteration of OGT
expression both in breast cancer cells (in vitro) and in animal
model (in vivo) also suggests a promising approach for anti-
cancer therapy (43). Research from both specimen samples and
cell lines is, therefore, needed to provide a better understand-
ing of O-GlcNAc biology in cancer. Taken together, this review
shows the current findings on O-GlcNAcylation in breast and
CRC. Many O-GlcNAc modified proteins are promising as poten-
tial novel cancer biomarkers or may be used in combination with
standard detection (e.g., serum biomarkers) to enhance specificity
and accuracy. Ongoing research will aim to detect these modi-
fied proteins in large-scale samples specifically and rapidly. Many
detection techniques such as advanced mass analyzers with new
fragmentation techniques including electron transfer dissociation
(ETD) are being developed. Specific O-GlcNAc modified pro-
teins in cancer specimens, therefore, are challenging to discover
as potential candidates for cancer diagnosis, especially in breast
and CRC.
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